We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir (RAL-PEP) (RAL-PEP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01576731
Recruitment Status : Completed
First Posted : April 12, 2012
Last Update Posted : April 1, 2015
Information provided by (Responsible Party):
Felipe Garcia, Hospital Clinic of Barcelona